Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Peripheral Nervous System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Trimetazidine × Clear all
NCT06459193 2025-03-30

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Minia University

Phase 1/2 Completed
60 enrolled

Hereditary Sensory and Autonomic Neuropathies, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡